Stockreport

Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Crinetics Pharmaceuticals, Inc.  (CRNX) 
Last crinetics pharmaceuticals, inc. earnings: 3/9 04:10 pm Check Earnings Report
PDF SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the first patient has been dosed in the CALM-CAH Phase [Read more]